Table 1.

Clinicopathologic characteristics of the patients with neuroblastoma and Aurora A mRNA and protein expression

Patient characteristicsmRNAProtein
nX ± SDPnX ± SDP
Age at diagnosis (y)
    ≤1283.10 ± 2.640.877251.37 ± 1.670.29
    >1392.98 ± 3.30281.82 ± 1.37
INSS stage
    I + II + IVS311.98 ± 1.340.007261.28 ± 1.240.0028
    III + IV363.94 ± 3.72272.85 ± 2.23
MYCN status
    Nonamplified492.64 ± 2.660.017361.30 ± 1.040.0029
    Amplified (>10 copies)144.84 ± 3.90112.50 ± 1.31
Histology
    Favorable282.42 ± 2.000.007231.03 ± 0.870.0006
    Unfavorable194.89 ± 3.94142.26 ± 1.11
Disease risk
    Low + intermediate 422.31 ± 1.800.019351.22 ± 0.940.011
    High224.74 ± 4.18162.11 ± 1.47
Relapse
    Yes194.59 ± 4.410.019142.42 ± 2.070.044
    No432.63 ± 2.00351.45 ± 1.17

NOTE: n, number of neuroblastoma tumor tissues tested; X, mean mRNA and protein expression levels between selected groups and determined by RT-PCR and Western blotting assay.